A crystal form, use and preparation method of a BRD4 inhibitor compound

CN116554171BActive Publication Date: 2024-11-26CHENGDU EASTON BIOPHARMACEUTICALS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310468492.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2022-05-30
Filing Date
2023-04-27
Publication Date
2024-11-26
Estimated Expiration
2043-04-27

AI Technical Summary

Technical Problem

同一药物的不同晶型在外观、溶解度、熔点、溶出度、生物等效性等方面可能会有显著不同,从而影响了药物的稳定性、生物利用度及疗效

Benefits of technology

[0085] 1. The various crystal forms prepared by this application are not easy to absorb moisture, have good solubility, and have excellent physical and chemical stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_4
    Figure SMS_4
  • Figure SMS_5
    Figure SMS_5
Patent Text Reader

Abstract

The present application relates to the field of drug crystal forms, and specifically to a new crystal form of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indoline-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide and a preparation method thereof. The crystal form of the compound of formula (I) obtained by the present invention has excellent physical stability and chemical stability, and is more suitable for clinical use; at the same time, the preparation conditions of various crystal forms of the present invention are mild and simple to operate. By controlling the key parameters in the crystal form preparation process, the preparation method of the present application can obtain a single crystal form, with good process reproducibility and high purity, so that the conditions for industrial production can be controlled, which is conducive to large-scale industrialization.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of drug crystal forms, and specifically relates to a crystal form of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide and a preparation method thereof. Background Art

[0002] Histone acetylation is an important part of epigenetic research. Acetylated histones can activate gene transcription through the action of DNA polymerase, RNA polymerase and transcription factors. The bromodomain and extra-terminal domain (BET) family belongs to the bromodomain protein family (BRDs), which is a class of evolutionarily highly conserved proteins that can recognize and bind to acetylated lysine residues in the tail of histones, recruit chromatin regulatory proteins, transcription factors, chromatin remodeling factors, etc., and thus play an important role in regulating gene transcription and chromatin remodeling. It is related to various biological processes such as cell growth, proliferation and differentiation, apoptosis and necrosis, and is an important epigenetic "reader".

[0003] So far, it has been found that the human genome encodes a total of 61 bromodomains, which are distributed in 46 different proteins. The BRDs family consists of four subtypes: BRD2, BRD3, BRD4, and BRDT, all of which contain two tandem bromodomains (BD1, BD2) and an extra-terminal (ET) domain. The two bromodomains are mainly responsible for recognizing and binding to acetylated lysine residues, while the ET domain interacts with auxiliary factors. Abnormal expression of BET proteins is associated with a variety of diseases. Although the four members of the BET family have similar structures, their biological functions are still different, especially BRD4 is closely related to a variety of diseases such as cancer and inflammation (Jung M et al., Epigenomics, 2015, 7(3): 487-501.).

[0004] Targeting BET proteins is beneficial for developing new therapeutic strategies targeting cancer, inflammation and viruses. Currently, small molecule inhibitors targeting BET proteins have entered the preclinical and clinical research stages, and are mainly used to treat cancer and autoimmune diseases. For example: JQ1, a BET small molecule inhibitor developed by Picaud et al. (Picaud S et al., Nature, 2010, 468 (7327): 1067-1073.) in 2010, related biological experiments have shown that JQ1 has potential therapeutic value for diseases such as cancer, cardiovascular disease, human immunodeficiency virus (HIV) infection and inflammation; GSK reported (WO2011054553A) that the BET small molecule inhibitor I-BET762 (GSK525762, Nicodeme E et al., Nature, 2010, 468, 7327) has significant effects in anti-inflammatory and anti-cancer aspects, and has now entered the Phase I / II clinical trial stage; RVX-208 developed by Resverlogix Corp (McLure KG et al., PLoS One, 2013, 8, 12: e83190.) is a quinazolinone inhibitor that selectively acts on BD2. Clinical data show that it has significant efficacy in treating diseases such as coronary artery syndrome, atherosclerosis and diabetes, and has now entered Phase III clinical trials; OTX015 developed by OncoEthix (Brand M. et al., ACS Chem Biol, 2015, 10(1): 22-39.) can act on solid tumors such as nuclear protein testis (NUT) midline carcinoma (NMC) and prostate cancer in children and young people, and has now entered Phase II clinical trials. Incyte disclosed compound INCB-057643 in patent application CN106414442A, which is in Phase I clinical trials; Abbive disclosed a class of selective BET protein inhibitors in WO2017177955A1, among which compound ABBV-744 showed better safety in preclinical studies and is currently in Phase I clinical trials.

[0005] Patent application PCT / CN2021 / 134454 (application date 2021.11.30) studies a class of BRD4 inhibitors, among which the compound shown in formula (I) prepared by Example 1, whose chemical name is N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, shows excellent BRD4 inhibitory effect and is a potential new drug for diseases related to BET proteins.

[0006]

[0007] The relevant crystal forms of compound I have not been reported in the literature. It is well known that the crystal form of a drug has an impact on the quality of the preparation and the production process. The study of the crystal form of a drug can provide a reference for formulation workers in terms of prescription development, new drug formulation design, optimization of production process, drug quality control, and clinical efficacy. Different crystal forms of the same drug may be significantly different in appearance, solubility, melting point, dissolution, bioequivalence, etc., thereby affecting the stability, bioavailability, and efficacy of the drug. Therefore, it is necessary to study the crystal form of compound (I) and develop one or more crystal forms with simple preparation methods, good solubility, high stability, high purity, not easy to absorb moisture, and suitable for industrial production. Summary of the invention

[0008] The present application aims to provide a variety of crystalline forms of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, some of which have good crystal stability and chemical stability and can be better used in clinical practice.

[0009] The present application provides a crystalline form A of a compound represented by formula (I), whose X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 4.20±0.2°, 7.19±0.2°, 8.32±0.2°, 8.77±0.2°, 10.13±0.2°, 15.20±0.2°, 15.69±0.2°, 18.48±0.2°, 20.95±0.2° and 25.92±0.2°.

[0010] Furthermore, the X-ray powder diffraction pattern of Form A has characteristic diffraction peaks at 2θ angles of 4.20±0.2°, 4.66±0.2°, 5.07±0.2°, 7.19±0.2°, 8.32±0.2°, 8.77±0.2°, 10.13±0.2°, 11.75±0.2°, 13.03±0.2°, 14.68±0.2°, 15.20±0.2°, 15.69±0.2°, 18.48±0.2°, 19.63±0.2°, 20.22±0.2°, 20.95±0.2°, 22.82±0.2°, 23.99±0.2°, 25.92±0.2° and 26.63±0.2°.

[0011] Furthermore, the crystalline form A in the present application uses Cu-Ka radiation, and the X-ray powder diffraction pattern expressed in 2θ angles, wherein at 4.20±0.2°, 4.66±0.2°, 5.07±0.2°, 7.19±0.2°, 8.32±0.2°, 8.77±0.2°, 10.13±0.2°, 11.75±0.2°, 13.03±0.2°, 14.10±0.2°, 15.80±0.2°, 16.90±0.2°, 17.70±0.2°, 18. There are characteristic diffraction peaks near 0.2°, 14.68±0.2°, 15.20±0.2°, 15.69±0.2°, 18.48±0.2°, 19.63±0.2°, 20.22±0.2°, 20.95±0.2°, 22.82±0.2°, 23.99±0.2°, 25.92±0.2° and 26.63±0.2°.

[0012] Preferably, the X-ray powder diffraction pattern of Form A is substantially as follows Figure 1 shown.

[0013] More preferably, the thermogravimetric analysis (TGA) spectrum of Form A is as follows: Figure 2 As shown in the figure, it can be seen that the weight loss of Form A in the range of 30-130°C is 5.8%.

[0014] The present application also relates to a method for preparing Form A, specifically: at room temperature, add an organic solvent to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide until it is dissolved, slowly add pure water dropwise for crystallization, fully stir for 3-24 hours, filter, and dry to obtain Form A.

[0015] Furthermore, the organic solvent is one or more of methanol, ethanol, isopropanol, trifluoroethanol, acetone, butanone, N-methylpyrrolidone, acetonitrile, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, and dimethyl sulfoxide.

[0016] This application A compound represented by formula (I) The crystalline form B has an X-ray powder diffraction pattern with characteristic peaks at 2θ angles of 7.44±0.2°, 8.27±0.2°, 9.28±0.2°, 12.81±0.2°, 16.49±0.2°, 18.34±0.2°, 19.25±0.2° and 23.46±0.2°.

[0017] Furthermore, the X-ray powder diffraction pattern of Form B at 2θ angles is 5.48±0.2°, 7.44±0.2°, 8.27±0.2°, 8.61±0.2°, 9.28±0.2°, 9.89±0.2°, 10.84±0.2°, 11.31±0.2°, 12.81±0.2°, 14.97±0.2°, There are characteristic diffraction peaks at 16.49±0.2°, 17.43±0.2°, 18.34±0.2°, 19.25±0.2°, 19.75±0.2°, 21.08±0.2°, 22.97±0.2°, 23.46±0.2°, 24.48±0.2°, 25.27±0.2° and 27.05±0.2°.

[0018] Furthermore, the Form B in the present application uses Cu-Ka radiation and an X-ray powder diffraction pattern expressed in 2θ angles, wherein at about 5.48±0.2°, 7.44±0.2°, 8.27±0.2°, 8.61±0.2°, 9.28±0.2°, 9.89±0.2°, 10.84±0.2°, 11.31±0.2°, 12.81±0.2°, There are characteristic diffraction peaks near 14.97±0.2°, 16.49±0.2°, 17.43±0.2°, 18.34±0.2°, 19.25±0.2°, 19.75±0.2°, 21.08±0.2°, 22.97±0.2°, 23.46±0.2°, 24.48±0.2°, 25.27±0.2° and 27.05±0.2°.

[0019] Preferably, the X-ray powder diffraction pattern of Form B is substantially as follows Figure 3 shown.

[0020] More preferably, the thermogravimetric analysis (TGA) spectrum of Form B is as follows: Figure 4 As shown in the figure, it can be seen that the weight loss of Form B in the range of 30-130°C is 7.0%.

[0021] The present application also relates to a method for preparing Form B, specifically: adding an organic solvent to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide until it is dissolved, slowly adding ethyl acetate dropwise for crystallization, stirring sufficiently for 3-24 hours, filtering, and drying to obtain Form B.

[0022] Furthermore, the organic solvent is one or more of methanol, ethanol, isopropanol, trifluoroethanol, acetone, butanone, acetonitrile, tetrahydrofuran, and isopropyl acetate.

[0023] The present application provides a crystalline form C of a compound represented by formula (I), whose X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 6.70±0.2°, 7.19±0.2°, 7.50±0.2°, 8.68±0.2°, 15.35±0.2°, 18.81±0.2°, 19.41±0.2°, 20.54±0.2° and 21.51±0.2°.

[0024] The present application provides a crystalline form C of a compound represented by formula (I), wherein the X-ray powder diffraction pattern at 2θ angles is 6.07±0.2°, 6.70±0.2°, 7.19±0.2°, 7.50±0.2°, 8.68±0.2°, 9.38±0.2°, 12.11±0.2°, 13.66±0.2°, 14.59±0.2 There are characteristic diffraction peaks at 15.35±0.2°, 17.70±0.2°, 18.04±0.2°, 18.17±0.2°, 18.81±0.2°, 19.41±0.2°, 20.54±0.2°, 21.51±0.2°, 23.30±0.2°, 24.03±0.2° and 25.24±0.2°.

[0025] Further, the Form C in the present application uses Cu-Ka radiation, and the X-ray powder diffraction pattern expressed in 2θ angles, wherein at about 6.07±0.2°, 6.70±0.2°, 7.19±0.2°, 7.50±0.2°, 8.68±0.2°, 9.38±0.2°, 12.11±0.2°, 13.66±0.2°, 14.59±0.2°, 15.80±0.2°, 16.70±0.2°, 17.60±0.2°, 18.90±0.2°, 19.70±0.2°, 20.80±0.2°, 21.30±0.2°, 23.70±0.2°, 24.70±0.2°, 25.80±0.2°, 26.70±0.2°, 27.70±0.2°, 28.70±0.2°, 29. There are characteristic diffraction peaks near 0.2°, 15.35±0.2°, 17.70±0.2°, 18.04±0.2°, 18.17±0.2°, 18.81±0.2°, 19.41±0.2°, 20.54±0.2°, 21.51±0.2°, 23.30±0.2°, 24.03±0.2° and 25.24±0.2°.

[0026] Preferably, the X-ray powder diffraction pattern of the crystalline form C is substantially as follows Figure 5 shown.

[0027] The thermogravimetric analysis (TGA) spectrum of the crystal form C is as follows Figure 6 As shown in the figure, it can be seen that the weight loss of Form C in the range of 30-130°C is 7.0%.

[0028] The present application also relates to a method for preparing Form C, specifically: adding an organic solvent to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide until it is dissolved, slowly adding toluene dropwise for crystallization, stirring sufficiently for 3-24 hours, filtering, and drying to obtain Form C.

[0029] Furthermore, the organic solvent is one or more of acetone, tetrahydrofuran, and 1,-dioxane.

[0030] The present application provides a crystalline form D of a compound represented by formula (I), whose X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 5.48±0.2°, 8.39±0.2°, 10.43±0.2°, 14.14±0.2°, 16.10±0.2°, 19.98±0.2°, 21.25±0.2°, 21.73±0.2°, and 23.29±0.2°.

[0031] Furthermore, the X-ray powder diffraction pattern of Form D has characteristic diffraction peaks at 2θ angles of 5.48±0.2°, 8.39±0.2°, 9.43±0.2°, 10.43±0.2°, 10.86±0.2°, 12.19±0.2°, 13.47±0.2°, 14.14±0.2°, 16.10±0.2°, 16.93±0.2°, 17.71±0.2°, 18.50±0.2°, 18.82±0.2°, 19.98±0.2°, 21.25±0.2°, 21.73±0.2°, 23.29±0.2°, 24.21±0.2°, 25.31±0.2° and 28.15±0.2°.

[0032] Furthermore, the crystalline form D in the present application uses Cu-Ka radiation and an X-ray powder diffraction pattern expressed in 2θ angles, wherein at about 5.48±0.2°, 8.39±0.2°, 9.43±0.2°, 10.43±0.2°, 10.86±0.2°, 12.19±0.2°, 13.47±0.2°, 14.14±0.2°, 16.1 There are characteristic diffraction peaks near 0±0.2°, 16.93±0.2°, 17.71±0.2°, 18.50±0.2°, 18.82±0.2°, 19.98±0.2°, 21.25±0.2°, 21.73±0.2°, 23.29±0.2°, 24.21±0.2°, 25.31±0.2° and 28.15±0.2°.

[0033] Preferably, the X-ray powder diffraction pattern of the crystalline form D is substantially as follows Figure 7 shown.

[0034] The thermogravimetric analysis (TGA) spectrum of the crystal form D is as follows Figure 8 As shown in the figure, it can be seen that the weight loss of crystal form D in the range of 30-130°C is 0.1%.

[0035] The present application also relates to a method for preparing Form D, specifically: adding ethanol to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide until it is dissolved, slowly adding diethyl ether dropwise for crystallization, stirring fully for 3-24 hours, filtering, and drying to obtain Form D.

[0036] The present application provides a crystalline form E of a compound represented by formula (I), whose X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 7.24±0.2°, 8.12±0.2°, 8.79±0.2°, 9.25±0.2°, 10.97±0.2°, 16.24±0.2°, 18.43±0.2°, 22.56±0.2° and 24.88±0.2°.

[0037] The present application provides a crystalline form E of a compound represented by formula (I), wherein the X-ray powder diffraction pattern at 2θ angles is 7.24±0.2°, 8.12±0.2°, 8.35±0.2°, 8.79±0.2°, 9.25±0.2°, 10.97±0.2°, 12.63±0.2°, 14.31±0.2°, 14.89±0.2°, 15.45±0.2 There are characteristic diffraction peaks at 16.17±0.2°, 16.24±0.2°, 17.51±0.2°, 17.85±0.2°, 18.43±0.2°, 19.82±0.2°, 20.92±0.2°, 21.93±0.2°, 22.56±0.2°, 23.32±0.2°, 24.88±0.2° and 25.73±0.2°.

[0038] Further, the crystalline form E in the present application uses Cu-Ka radiation, and the X-ray powder diffraction pattern expressed in 2θ angles, wherein at about 7.24±0.2°, 8.12±0.2°, 8.35±0.2°, 8.79±0.2°, 9.25±0.2°, 10.97±0.2°, 12.63±0.2°, 14.31±0.2°, 14.89±0.2°, 15.45 There are characteristic diffraction peaks near 16.17±0.2°, 16.24±0.2°, 17.51±0.2°, 17.85±0.2°, 18.43±0.2°, 19.82±0.2°, 20.92±0.2°, 21.93±0.2°, 22.56±0.2°, 23.32±0.2°, 24.88±0.2° and 25.73±0.2°.

[0039] Preferably, the X-ray powder diffraction pattern of the crystalline form E is substantially as follows Fig. 9 shown.

[0040] The thermogravimetric analysis (TGA) spectrum of the crystal form E is as follows Fig.10 As shown in the figure, it can be seen that the weight loss of Form E in the range of 30-130°C is 8.9%.

[0041] The present application also relates to a method for preparing Form E, specifically: adding ethanol to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide until it dissolves, slowly adding methyl tert-butyl ether dropwise for crystallization, stirring sufficiently for 3-24 hours, filtering, and drying to obtain Form E.

[0042] The present application provides a crystalline form F of a compound represented by formula (I), whose X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 5.16±0.2°, 7.47±0.2°, 10.84±0.2°, 13.58±0.2°, 17.87±0.2°, 18.90±0.2°, 19.34±0.2°, 19.78±0.2° and 22.81±0.2°.

[0043] Furthermore, the X-ray powder diffraction pattern of Form F has characteristic diffraction peaks at 2θ angles of 5.16±0.2°, 7.47±0.2°, 8.32±0.2°, 9.45±0.2°, 10.25±0.2°, 10.84±0.2°, 13.58±0.2°, 15.20±0.2°, 16.60±0.2°, 17.87±0.2°, 18.25±0.2°, 18.90±0.2°, 19.34±0.2°, 19.78±0.2°, 20.71±0.2°, 22.37±0.2°, 22.81±0.2°, 23.52±0.2°, 24.60±0.2° and 26.89±0.2°.

[0044] Furthermore, the Form F in the present application uses Cu-Ka radiation and an X-ray powder diffraction pattern expressed in 2θ angles, wherein at about 5.16±0.2°, 7.47±0.2°, 8.32±0.2°, 9.45±0.2°, 10.25±0.2°, 10.84±0.2°, 13.58±0.2°, 15.20±0.2°, 16.6 There are characteristic diffraction peaks near 0±0.2°, 17.87±0.2°, 18.25±0.2°, 18.90±0.2°, 19.34±0.2°, 19.78±0.2°, 20.71±0.2°, 22.37±0.2°, 22.81±0.2°, 23.52±0.2°, 24.60±0.2° and 26.89±0.2°.

[0045] Preferably, the X-ray powder diffraction pattern of the crystalline form F is substantially as follows Fig.11 shown.

[0046] The thermogravimetric analysis (TGA) spectrum of the crystal form F is as follows Fig.12 As shown in the figure, it can be seen that the weight loss of Form F in the range of 30-130°C is 5.0%.

[0047] The present application also relates to a method for preparing Form F, specifically: adding acetone to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide until it is dissolved, slowly adding diethyl ether or methyl tert-butyl ether dropwise for crystallization, stirring fully for 3-24 hours, filtering, and drying to obtain Form F.

[0048] The present application provides a crystalline form G of a compound represented by formula (I), whose X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 10.03±0.2°, 11.36±0.2°, 12.88±0.2°, 14.93±0.2°, 15.73±0.2°, 17.08±0.2°, 19.17±0.2°, 20.64±0.2° and 22.10±0.2°.

[0049] Furthermore, the X-ray powder diffraction pattern of Form G has characteristic diffraction peaks at 2θ angles of 6.87±0.2°, 10.03±0.2°, 11.36±0.2°, 12.88±0.2°, 13.70±0.2°, 14.93±0.2°, 15.73±0.2°, 16.62±0.2°, 17.08±0.2°, 18.40±0.2°, 19.17±0.2°, 20.64±0.2°, 20.96±0.2°, 21.33±0.2°, 22.10±0.2°, 23.52±0.2°, 24.10±0.2°, 25.72±0.2°, 26.07±0.2° and 27.63±0.2°.

[0050] Furthermore, the X-ray powder diffraction pattern of the crystalline form G in the present application using Cu-Ka radiation, expressed in 2θ angles, wherein the X-ray powder diffraction pattern is expressed in 2θ angles at about 6.87±0.2°, 10.03±0.2°, 11.36±0.2°, 12.88±0.2°, 13.70±0.2°, 14.93±0.2°, 15.73±0.2°, 16.62±0.2°, 17. There are characteristic diffraction peaks near 08±0.2°, 18.40±0.2°, 19.17±0.2°, 20.64±0.2°, 20.96±0.2°, 21.33±0.2°, 22.10±0.2°, 23.52±0.2°, 24.10±0.2°, 25.72±0.2°, 26.07±0.2° and 27.63±0.2°.

[0051] Preferably, the X-ray powder diffraction pattern of the crystalline form G is substantially as follows Fig.13 shown.

[0052] The thermogravimetric analysis (TGA) spectrum of the crystal form G is as follows Fig.14 As shown in the figure, it can be seen that the weight loss of crystal form G in the range of 30-130°C is 0.7%.

[0053] The present application also relates to a method for preparing Form G, specifically: adding 1,4-dioxane to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide until it is dissolved, slowly adding diethyl ether, methyl tert-butyl ether or ethyl acetate dropwise for crystallization, stirring fully for 3-24 hours, filtering, and drying to obtain Form G.

[0054] The present application provides a crystalline form H of a compound represented by formula (I), whose X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 8.70±0.2°, 14.89±0.2°, 16.63±0.2°, 17.19±0.2°, 17.80±0.2°, 19.08±0.2°, 21.55±0.2° and 22.77±0.2°.

[0055] The present application provides a crystalline form H of a compound represented by formula (I), wherein the X-ray powder diffraction pattern at 2θ angles is 8.70±0.2°, 9.35±0.2°, 10.58±0.2°, 11.42±0.2°, 12.48±0.2°, 14.89±0.2°, 16.63±0.2°, 17.19±0.2°, 17.80±0.2°, There are characteristic diffraction peaks at .2°, 18.56±0.2°, 19.08±0.2°, 19.69±0.2°, 19.97±0.2°, 21.02±0.2°, 21.55±0.2°, 22.77±0.2°, 24.44±0.2°, 25.33±0.2°, 26.89±0.2° and 29.82±0.2°.

[0056] Further, the crystal form H in the present application uses Cu-Ka radiation, and the X-ray powder diffraction pattern expressed in 2θ angles, wherein at about 8.70±0.2°, 9.35±0.2°, 10.58±0.2°, 11.42±0.2°, 12.48±0.2°, 14.89±0.2°, 16.63±0.2°, 17.19±0.2°, 17.8 There are characteristic diffraction peaks near 0±0.2°, 18.56±0.2°, 19.08±0.2°, 19.69±0.2°, 19.97±0.2°, 21.02±0.2°, 21.55±0.2°, 22.77±0.2°, 24.44±0.2°, 25.33±0.2°, 26.89±0.2° and 29.82±0.2°.

[0057] Preferably, the X-ray powder diffraction pattern of the crystalline form H is substantially as follows Fig.15 shown.

[0058] The thermogravimetric analysis (TGA) spectrum of the crystal form H is as follows Fig.16 As shown in the figure, it can be seen that the weight loss of crystal form H in the range of 30-130°C is 0.5%. The present application also relates to a method for preparing crystal form H, specifically: adding 1, -dioxane to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide until it is dissolved, slowly adding dichloromethane dropwise for crystallization, fully stirring for 3-24 hours, filtering, and drying to obtain crystal form H.

[0059] The present application provides a crystalline form I of a compound represented by formula (I), whose X-ray powder diffraction pattern is substantially as follows: Fig.17 shown.

[0060] The present application also relates to a method for preparing Form I, specifically: adding diethyl ether to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirring at room temperature for 3-24 hours, filtering, and drying to obtain Form I.

[0061] The present application provides a crystalline form J of a compound represented by formula (I), whose X-ray powder diffraction pattern is substantially as follows: Fig.18 shown.

[0062] The thermogravimetric analysis (TGA) spectrum of the crystal form J is as follows Fig.19 As shown in the figure, it can be seen that the weight loss of crystal form J in the range of 30-130°C is 0.8%.

[0063] The present application also relates to a method for preparing Form J, which is specifically: adding ethanol to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirring and dissolving, slowly adding methyl tert-butyl ether dropwise for crystallization, stirring fully for 3-24 hours, filtering, and drying to obtain Form J.

[0064] The present application provides a crystalline form L of a compound represented by formula (I), whose X-ray powder diffraction pattern is substantially as follows: Fig. 20 shown.

[0065] The thermogravimetric analysis (TGA) spectrum of the crystal form L is as follows Fig.21 As shown in the figure, it can be seen that the weight loss of crystal form L in the range of 30-150°C is 2.0%.

[0066] The present application also relates to a method for preparing crystal form L, specifically: adding isopropanol to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirring thoroughly for 3-24 hours, filtering, and drying to obtain crystal form L.

[0067] The present application provides a crystalline form M of a compound represented by formula (I), whose X-ray powder diffraction pattern is substantially as follows: Fig. 22 shown.

[0068] The thermogravimetric analysis (TGA) spectrum of the crystal form M is as follows Fig.23 As shown in the figure, it can be seen that the weight loss of crystal form M in the range of 30-150°C is 3.0%.

[0069] The present application also relates to a method for preparing crystal form M, specifically: adding ethyl formate to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirring thoroughly for 3-24 hours, filtering, and drying to obtain crystal form M.

[0070] The present application provides a crystalline form N of a compound represented by formula (I), whose X-ray powder diffraction pattern is substantially as follows: Fig.24 shown.

[0071] The thermogravimetric analysis (TGA) spectrum of the crystal form N is as follows Fig.25 As shown in the figure, it can be seen that the weight loss of crystal form N in the range of 30-130°C is 3.8%.

[0072] The present application also relates to a method for preparing crystal form N, specifically: adding ethylene glycol dimethyl ether to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirring thoroughly for 3-24 hours, filtering, and drying to obtain crystal form N.

[0073] The present application provides a crystalline form O of a compound represented by formula (I), whose X-ray powder diffraction pattern is substantially as follows: Fig.26 shown.

[0074] The thermogravimetric analysis (TGA) spectrum of the crystal form O is as follows Fig. 27As shown in the figure, it can be seen that the weight loss of crystal form O in the range of 30-150°C is 1.9%. The present application also relates to a method for preparing crystal form O, specifically: adding tetrahydrofuran to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirring thoroughly for 3-24 hours, filtering, and drying to obtain crystal form O.

[0075] The present application provides a crystalline form P of a compound represented by formula (I), whose X-ray powder diffraction pattern is substantially as follows: Fig.28 shown.

[0076] The thermogravimetric analysis (TGA) spectrum of the crystal form P is as follows Fig.29 As shown in the figure, it can be seen that the weight loss of crystal form P in the range of 30-160°C is 5.5%.

[0077] The present application also relates to a method for preparing crystal form P, specifically: adding ethyl formate to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirring thoroughly for 3-24 hours, filtering, and drying to obtain crystal form P.

[0078] The present application provides a crystalline form Q of a compound represented by formula (I), whose X-ray powder diffraction pattern is substantially as follows: Fig.30 shown.

[0079] The present application also relates to a method for preparing crystal form Q, specifically: adding dimethyl carbonate to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirring thoroughly for 3-24 hours, filtering, and drying to obtain crystal form Q.

[0080] The present application provides a crystalline form R of a compound represented by formula (I), whose X-ray powder diffraction pattern is substantially as follows: Fig.31 shown.

[0081] The present application also relates to a method for preparing crystal form R, specifically: adding dichloromethane to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirring thoroughly for 3-24 hours, filtering, and drying to obtain crystal form R.

[0082] The present application provides a crystalline form S of a compound represented by formula (I), whose X-ray powder diffraction pattern is substantially as follows: Fig.32 shown.

[0083] The present application also relates to a method for preparing crystal form S, specifically: add 2-methyltetrahydrofuran to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stir well for 3-24 hours, filter, and dry to obtain crystal form S.

[0084] The beneficial effects brought by the present invention are:

[0085] 1. The various crystal forms prepared in this application are not easy to absorb moisture, have good solubility, and have excellent physical and chemical stability.

[0086] 2. The preparation conditions of various crystal forms in the present application are mild and the operation is simple; by controlling the key parameters in the crystal preparation process, the preparation method of the present application can obtain a single crystal form with good process reproducibility and high purity, so that the conditions for industrial production can be controlled, which is conducive to large-scale industrialization. BRIEF DESCRIPTION OF THE DRAWINGS

[0087] Figure 1 This is the XRD pattern of Form A obtained in Example 1.

[0088] Figure 2 This is the TGA spectrum of Form A obtained in Example 1.

[0089] Figure 3 This is the XRD pattern of Form B obtained in Example 5.

[0090] Figure 4 This is the TGA spectrum of Form B obtained in Example 5.

[0091] Figure 5 This is the XRD pattern of Form C obtained in Example 6.

[0092] Figure 6 This is the TGA spectrum of Form C obtained in Example 6.

[0093] Figure 7 This is the XRD pattern of Form D obtained in Example 7.

[0094] Figure 8 This is the TGA spectrum of Form D obtained in Example 7.

[0095] Fig. 9 This is the XRD pattern of Form E obtained in Example 8.

[0096] Fig.10This is the TGA spectrum of Form E obtained in Example 8.

[0097] Fig.11 This is the XRD pattern of Form F obtained in Example 9.

[0098] Fig.12 This is the TGA spectrum of Form F obtained in Example 9.

[0099] Fig.13 This is the XRD pattern of Form G obtained in Example 10.

[0100] Fig.14 This is the TGA spectrum of Form G obtained in Example 10.

[0101] Fig.15 This is the XRD pattern of Form H obtained in Example 11.

[0102] Fig.16 This is the TGA spectrum of Form H obtained in Example 11.

[0103] Fig.17 This is the XRD pattern of Form I obtained in Example 12.

[0104] Fig.18 This is the XRD pattern of Form J obtained in Example 13.

[0105] Fig.19 This is the TGA spectrum of Form J obtained in Example 13.

[0106] Fig. 20 This is the XRD pattern of Form L obtained in Example 14.

[0107] Fig.21 This is the TGA spectrum of Form L obtained in Example 14.

[0108] Fig. 22 This is the XRD pattern of Form M obtained in Example 15.

[0109] Fig.23 This is the TGA spectrum of Form M obtained in Example 15.

[0110] Fig.24 This is the XRD pattern of Form N obtained in Example 16.

[0111] Fig.25 This is the TGA spectrum of Form N obtained in Example 16.

[0112] Fig.26 This is the XRD pattern of Form O obtained in Example 17.

[0113] Fig. 27 This is the TGA spectrum of Form O obtained in Example 17.

[0114] Fig.28 This is the XRD pattern of Form P obtained in Example 18.

[0115] Fig.29 This is the TGA spectrum of Form P obtained in Example 18.

[0116] Fig.30 This is the XRD pattern of Form Q obtained in Example 19.

[0117] Fig.31 This is the XRD pattern of Form R obtained in Example 20.

[0118] Fig.32 This is the XRD pattern of Form S obtained in Example 21.

[0119] Fig.33 This is the XRD pattern of the amorphous product obtained in Example 22.

[0120] Fig.34 This is the TGA spectrum of the amorphous product obtained in Example 22.

[0121] Fig.35 This is the XRD comparison spectrum of Form A before and after the influencing factors are placed.

[0122] Fig.36 This is the XRD comparison spectrum of Form G before and after the influencing factors are placed.

[0123] Fig.37 This is the XRD comparison spectrum of Form H before and after the influencing factors are placed.

[0124] Fig.38 It is the DVS curve of Form A.

[0125] Fig.39 This is the DVS curve of Form B.

[0126] Fig.40 This is the DVS curve of Form F.

[0127] Fig.41 This is the DVS curve of Form G.

[0128] Fig.42 This is the DVS curve of Form H.

[0129] Fig.43 It is an amorphous DVS curve. DETAILED DESCRIPTION

[0130] The present invention is further described in detail below in conjunction with the embodiments, but the present invention is not limited thereto. Any equivalent substitutions in the art made according to the disclosure of the present invention shall fall within the protection scope of the present invention.

[0131] The abbreviations used in this application are explained as follows:

[0132] XRD: X-ray powder diffraction

[0133] The X-ray powder diffraction (XRD) test described in this application is collected using a Malvern Panalytical Empyrea powder diffractometer, and the specific parameters are as follows:

[0134]

[0135]

[0136] TGA: Thermogravimetric Analyzer

[0137] The thermogravimetric analysis (TGA) described in the present application was performed using a METTLER TOLEDO model TGA-2, with a heating rate of 10°C / min, a temperature range of 30-300°C, and a nitrogen purge rate of 20 mL / min during the test.

[0138] Room temperature: 15~30℃.

[0139] Preparation Example of the compound shown in Formula I:

[0140] Synthesis route:

[0141]

[0142] Step 1: Ethyl 4-(indolin-1-yl)thiophene-2-carboxylate (1-1)

[0143] Ethyl 4-bromothiophene-2-carboxylate (2.52 g, 10.55 mmol), indoline (1.92 g, 13.72 mmol), potassium acetate (1.26 g, 12.66 mmol), ligand Xantphos (187 mg, 0.3 mmol) and toluene (50 mL) were added to a 50 mL three-necked flask, and the mixture was replaced with nitrogen three times. Pd2(dba)3 catalyst (295 mg, 0.3 mmol) was added under nitrogen flow, and the mixture was heated to 85°C for 2 hours under nitrogen protection. TLC monitoring (PE / EA=10 / 1) showed that the raw materials reacted completely. The reaction solution was cooled to room temperature, diluted with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated sodium chloride solution, the organic layer was dried overnight with anhydrous sodium sulfate, the desiccant was filtered, the filtrate was decompressed to recover the solvent, and purified by column chromatography to obtain 1.96 g of off-white solid 1-1.

[0144] Step 2: 2-(4-(Indolin-1-yl)thiophen-2-yl)propan-2-ol (1-2)

[0145] The intermediate 1-1 (1.92 g, 6.89 mmol) of the above step was added to a 50 mL three-necked flask, THF (30 mL) was added and stirred to dissolve, and the mixture was cooled to below -5°C in an ice bath, and a THF solution of methyl magnesium bromide (2M, 7.58 mL, 15.16 mmol) was added dropwise in batches. After the addition, the mixture was cooled in an ice bath, and the mixture was stirred and reacted for 2 hours. The mixture was naturally heated to room temperature and stirred and reacted for 2 hours. The reaction progress was monitored by TLC. After the reaction of the raw materials was complete, a saturated ammonium chloride solution was added dropwise to quench the reaction, and the mixture was extracted with ethyl acetate and washed with saturated brine. The organic layer was dried overnight with anhydrous sodium sulfate, the desiccant was filtered, the filtrate was decompressed to recover the solvent, and the mixture was purified by column chromatography to obtain 1.53 g of intermediate 1-2).

[0146] Step 3: 2-(5-Bromo-4-(indolin-1-yl)thiophen-2-yl)propan-2-ol (1-3)

[0147] The intermediate 1-2 (1.85 g, 7.00 mmol) of the above step was added to a 50 mL three-necked flask, THF (40 mL) was added and stirred to dissolve, and the mixture was cooled to below -65 ° C in a dry ice bath, and a cyclohexane solution of n-butyl lithium (2.5 M, 6.2 mL, 15.4 mmol) was added dropwise in batches. After the addition, the mixture was cooled in a dry ice bath, and the reaction was continued to stir for 1 hour. Subsequently, N-bromosuccinimide (1.39 g, 7.8 mmol) was added and the reaction was stirred for 3 hours. The reaction progress was monitored by TLC. After the reaction of the raw materials was complete, a saturated ammonium chloride solution was added dropwise to quench the reaction, and the mixture was extracted with ethyl acetate and washed with saturated brine. The organic layer was dried overnight with anhydrous sodium sulfate, the desiccant was filtered, the filtrate was decompressed to recover the solvent, and the mixture was purified by column chromatography to obtain 1.66 g of the intermediate 1-3.

[0148] Step 4: N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolin-1-yl)thiophen-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (I)

[0149] The intermediate 1-3 (0.53 g, 1.54 mmol), intermediate Ia-1 (0.59 g, 1.70 mmol), ligand Xphos (27 mg, 0.04 mmol), cesium carbonate (0.77 g, 2.31 mmol) of the above step were added to a 50 mL three-necked flask, and 1,4-dioxane solvent (15 mL) was added and stirred to mix evenly, replaced with nitrogen 3 times, and Pd2 (dba) 3 catalyst (43.0 mg, 0.04 mmol) was added under nitrogen flow, and nitrogen was replaced again 2 times, and the temperature was raised to 105 ° C under nitrogen protection for 8 hours. TLC monitored the reaction progress, and when the raw material reacted completely, it was diluted with ethyl acetate, washed with water, and washed with saturated brine, and the organic layer was dried overnight with anhydrous sodium sulfate, the desiccant was filtered, and the filtrate was decompressed to recover the solvent, Flash fast column purification was performed, and most of the organic solvent was recovered, and lyophilized to obtain 305 mg of compound I.

[0150] ESI-MS: m / z = 477.2 (M+H) + ;

[0151] 1 H NMR(400MHz,d6-DMSO)δ12.27(s,-NH,1H),8.37(s,-NH,1H),7.34(s,1H),7.05(s,1H),7.01(m,1H),6.92(s,1H),6.55(m,1H),6. 35(m,1H),6.33(m,1H),5.53(s,-OH,1H),3.72(t,J=2.4Hz,2H),3.34(s,3H),3.24(s,2H),2.96(m,2H),1.53(m,6H),1.13(m,3H).

[0152] Example 1: Preparation of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide Form A

[0153] To 30 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, add 200 μL of ethanol and stir to dissolve. Slowly add 600 μL of pure water dropwise at room temperature to crystallize. After the addition is completed, continue stirring for 24 hours, filter, and dry to obtain an off-white solid.

[0154] This crystalline form was named Form A.

[0155] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and its spectrum had the diffraction angle, interplanar spacing and relative intensity shown in Table 1:

[0156] Table 1 Diffraction angle, interplanar spacing and relative intensity of Form A

[0157]

[0158] The error of the 2θ diffraction angle is ±0.20°.

[0159] Furthermore, the crystalline form A prepared in Example 1 has substantially Figure 1 The X-ray powder diffraction pattern is shown.

[0160] The thermogravimetric analysis (TGA) spectrum of the crystal form A is as follows Figure 2 As shown in the figure, it can be seen that the weight loss of Form A in the range of 30-130°C is 5.8%. Example 2: Preparation of Form A of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide

[0161] 150 μL of acetone was added to 30 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, and the mixture was stirred and dissolved. 1.5 mL of pure water was slowly added dropwise at room temperature for crystallization. After the addition was completed, stirring was continued for 24 hours, filtered, and dried to obtain an off-white solid. Its powder diffraction pattern and thermogravimetric analysis pattern were basically consistent with those in Example 1.

[0162] Example 3: Preparation of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide Form A

[0163] 70 μL of acetonitrile was added to 30 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, and stirred to dissolve. 1 mL of pure water was slowly added dropwise at room temperature for crystallization. After the addition was completed, stirring was continued for 24 hours, filtered, and dried to obtain an off-white solid. Its powder diffraction pattern and thermogravimetric analysis pattern were basically consistent with those in Example 1.

[0164] Example 4: Preparation of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide Form A

[0165] 30 μL of tetrahydrofuran was added to 30 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, and stirred to dissolve. 1 mL of pure water was slowly added dropwise at room temperature for crystallization. After the addition was completed, stirring was continued for 24 hours, filtered, and dried to obtain an off-white solid. Its powder diffraction pattern and thermogravimetric analysis pattern were basically consistent with those in Example 1.

[0166] Example 5: Preparation of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide Form B

[0167] To 30 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, add 30 μL of acetone and stir to dissolve. Slowly add 600 μL of ethyl acetate dropwise at room temperature to crystallize. After the addition is completed, continue stirring for 24 hours, filter, and dry to obtain an off-white solid.

[0168] This crystal form was named as Form B.

[0169] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and its spectrum had the diffraction angle, interplanar spacing and relative intensity shown in Table 2:

[0170] Table 2 Diffraction angle, interplanar spacing and relative intensity of Form B

[0171]

[0172] The error of the 2θ diffraction angle is ±0.20°.

[0173] Furthermore, the crystalline form B prepared in Example 5 has substantially Figure 3 The X-ray powder diffraction pattern is shown.

[0174] The thermogravimetric analysis (TGA) spectrum of the crystal form B is as follows Figure 4As shown in the figure, it can be seen that the weight loss of Form B in the range of 30-130°C is 7.0%. Example 6: Preparation of Form C of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide

[0175] To 30 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, add 30 μL of acetone and stir to dissolve. Slowly add 600 μL of toluene dropwise at room temperature to crystallize. After the addition is completed, continue stirring for 24 hours, filter, and dry to obtain an off-white solid.

[0176] This crystal form was named as Crystal Form C.

[0177] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and its spectrum had the diffraction angle, interplanar spacing and relative intensity shown in Table 3:

[0178] Table 3 Diffraction angle, interplanar spacing and relative intensity of Form C

[0179]

[0180] The error of the 2θ diffraction angle is ±0.20°.

[0181] Furthermore, the crystalline form C prepared in Example 6 has substantially Figure 5 The X-ray powder diffraction pattern is shown.

[0182] The thermogravimetric analysis (TGA) spectrum of the crystal form C is as follows Figure 6 As shown in the figure, it can be seen that the weight loss of crystal form C in the range of 30-130°C is 7.0%. Example 7: Preparation of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophen-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide crystal form D

[0183] To 30 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, add 30 μL of ethanol and stir to dissolve. Slowly add 600 μL of ether dropwise at room temperature for crystallization. After the addition is complete, continue stirring for 24 hours, filter, and dry to obtain an off-white solid.

[0184] This crystal form was named as Crystal Form D.

[0185] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and its spectrum had the diffraction angle, interplanar spacing and relative intensity shown in Table 4:

[0186] Table 4 Diffraction angle, interplanar spacing and relative intensity of Form D

[0187]

[0188] The error of the 2θ diffraction angle is ±0.20°.

[0189] Furthermore, the crystalline form D prepared in Example 7 has substantially Figure 7 The X-ray powder diffraction pattern is shown.

[0190] The thermogravimetric analysis (TGA) spectrum of the crystal form D is as follows Figure 8 As shown in the figure, it can be seen that the weight loss of crystal form D in the range of 30-130°C is 0.1%. Example 8: Preparation of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophen-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide crystal form E

[0191] To 30 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, 30 μL of ethanol was added and the mixture was stirred to dissolve. At room temperature, 600 μL of methyl tert-butyl ether was slowly added dropwise to crystallize. After the addition was completed, stirring was continued for 24 hours. The mixture was filtered and dried to obtain an off-white solid.

[0192] This crystal form was named as Crystal Form E.

[0193] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and its spectrum had the diffraction angle, interplanar spacing and relative intensity shown in Table 5:

[0194] Table 5 Diffraction angle, interplanar spacing and relative intensity of Form E

[0195]

[0196] The error of the 2θ diffraction angle is ±0.20°.

[0197] Furthermore, the crystalline form E prepared in Example 8 has substantially Fig. 9 The X-ray powder diffraction pattern is shown.

[0198] The thermogravimetric analysis (TGA) spectrum of the crystal form E is as follows Fig.10As shown in the figure, it can be seen that the weight loss of Form E in the range of 30-130°C is 8.9%. Example 9: Preparation of Form F of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide

[0199] To 30 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, add 100 μL of acetone and stir to dissolve. Slowly add 300 μL of methyl tert-butyl ether dropwise at room temperature to crystallize. After the addition is completed, continue stirring for 24 hours, filter, and dry to obtain an off-white solid.

[0200] This crystal form was named as Form F.

[0201] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and its spectrum had the diffraction angle, interplanar spacing and relative intensity shown in Table 6:

[0202] Table 6 Diffraction angle, interplanar spacing and relative intensity of Form F

[0203]

[0204]

[0205] The error of the 2θ diffraction angle is ±0.20°.

[0206] Furthermore, the crystalline form F prepared in Example 9 has substantially Fig.11 The X-ray powder diffraction pattern is shown.

[0207] The thermogravimetric analysis (TGA) spectrum of the crystal form F is as follows Fig.12 As shown in the figure, it can be seen that the weight loss of Form F in the range of 30-130°C is 5.0%. Example 10: Preparation of Form G of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide

[0208] To 30 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, 30 μL of 1,4-dioxane was added and stirred to dissolve. 600 μL of ethyl acetate was slowly added dropwise at room temperature for crystallization. After the addition was completed, stirring was continued for 24 h. The mixture was filtered and dried to obtain an off-white solid.

[0209] This crystal form was named as Crystal Form G.

[0210] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and its spectrum had the diffraction angle, interplanar spacing and relative intensity shown in Table 7:

[0211] Table 7 Diffraction angle, interplanar spacing and relative intensity of Form G

[0212]

[0213] The error of the 2θ diffraction angle is ±0.20°.

[0214] Furthermore, the crystalline form G prepared in Example 10 has substantially Fig.13 The X-ray powder diffraction pattern is shown.

[0215] The thermogravimetric analysis (TGA) spectrum of the crystal form G is as follows Fig.14 As shown in the figure, it can be seen that the weight loss of Form G in the range of 30-130°C is 0.7%. Example 11: Preparation of Form H of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide

[0216] To 30 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, 30 μL of 1,4-dioxane was added and stirred to dissolve. At room temperature, 600 μL of dichloromethane was slowly added dropwise to crystallize. After the addition was completed, stirring was continued for 24 hours. The mixture was filtered and dried to obtain an off-white solid.

[0217] This crystal form was named as Crystal Form H.

[0218] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and its spectrum had the diffraction angle, interplanar spacing and relative intensity shown in Table 8:

[0219] Table 8 Diffraction angle, interplanar spacing and relative intensity of Form H

[0220]

[0221] The error of the 2θ diffraction angle is ±0.20°.

[0222] Furthermore, the crystalline form H prepared in Example 11 has substantially Fig.15 The X-ray powder diffraction pattern is shown.

[0223] The thermogravimetric analysis (TGA) spectrum of the crystal form H is as follows Fig.16 As shown in the figure, it can be seen that the weight loss of Form H in the range of 30-130°C is 0.5%. Example 12: Preparation of Form I of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide

[0224] 56 mL of ether was added to 2.54 g of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolin-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide amorphous form, stirred at room temperature for 3 h, filtered, and dried to obtain an off-white solid. This crystal form was named Crystal Form I.

[0225] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and it had substantially the same Fig.17 Example 13: Preparation of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide Form J

[0226] 4 mL of ethanol was added to 1.50 g of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide amorphous form, and the mixture was stirred to dissolve. 40 mL of methyl tert-butyl ether was slowly added dropwise at room temperature for crystallization. After the addition was completed, stirring was continued for 24 hours, and the mixture was filtered and dried to obtain an off-white solid. The crystal form was named Crystal Form J.

[0227] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and it had substantially the same Fig.18 The X-ray powder diffraction pattern is shown.

[0228] The thermogravimetric analysis (TGA) spectrum of the crystal form J is as follows Fig.19As shown in the figure, it can be seen that the weight loss of crystal form J in the range of 30-130°C is 0.8%. Example 14: Preparation of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophen-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide crystal form L

[0229] 100 μL of isopropanol was added to 20 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirred at room temperature for 20 h, filtered, and dried to obtain an off-white solid. This crystal form was named Crystal Form L.

[0230] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and it had substantially the same Fig. 20 The X-ray powder diffraction pattern is shown.

[0231] The thermogravimetric analysis (TGA) spectrum of the crystal form L is as follows Fig.21 As shown in the figure, it can be seen that the weight loss of crystal form L in the range of 30-150°C is 2.0%. Example 15: Preparation of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophen-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide crystal form M

[0232] 200 μL of ethyl formate was added to 20 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolin-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirred at room temperature for 20 h, filtered, and dried to obtain an off-white solid. This crystal form was named Crystal Form M.

[0233] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and it had substantially the same Fig. 22 The X-ray powder diffraction pattern is shown.

[0234] The thermogravimetric analysis (TGA) spectrum of the crystal form M is as follows Fig.23 As shown in the figure, it can be seen that the weight loss of crystal form M in the range of 30-150°C is 3.0%.

[0235] Example 16: Preparation of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide Form N

[0236] 100 μL of ethylene glycol dimethyl ether was added to 20 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolin-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirred at room temperature for 20 h, filtered, and dried to obtain an off-white solid. This crystal form was named Crystal Form N.

[0237] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and it had substantially the same Fig.24 The X-ray powder diffraction pattern is shown.

[0238] The thermogravimetric analysis (TGA) spectrum of the crystal form N is as follows Fig.25 As shown in the figure, it can be seen that the weight loss of crystal form N in the range of 30-130°C is 3.8%.

[0239] Example 17: Preparation of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide Form O

[0240] 100 μL of tetrahydrofuran was added to 20 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolin-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirred at room temperature for 20 h, filtered, and dried to obtain an off-white solid. This crystal form was named Crystal Form O.

[0241] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and it had substantially the same Fig.26 The X-ray powder diffraction pattern is shown.

[0242] The thermogravimetric analysis (TGA) spectrum of the crystal form O is as follows Fig. 27 As shown in the figure, it can be seen that the weight loss of crystal form O in the range of 30-150°C is 1.9%.

[0243] Example 18: Preparation of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide Form P

[0244] 200 μL of ethyl formate was added to 20 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolin-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirred at room temperature for 20 h, filtered, and dried to obtain an off-white solid. This crystal form was named Crystal Form P.

[0245] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and it had substantially the same Fig.28 The X-ray powder diffraction pattern is shown.

[0246] The thermogravimetric analysis (TGA) spectrum of the crystal form P is as follows Fig.29 As shown in the figure, it can be seen that the weight loss of crystal form P in the range of 30-160°C is 5.5%.

[0247] Example 19: Preparation of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide Form Q

[0248] 300 μL of dimethyl carbonate was added to 20 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolin-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirred at room temperature for 20 h, filtered, and dried to obtain an off-white solid. This crystal form was named Crystal Form Q.

[0249] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and it had substantially the same Fig.30 The X-ray powder diffraction pattern is shown.

[0250] Example 20: Preparation of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide Form R

[0251] 200 μL of dichloromethane was added to 20 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirred at room temperature for 20 h, filtered, and dried to obtain an off-white solid. This crystal form was named Crystal Form R.

[0252] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and it had substantially the same Fig.31 The X-ray powder diffraction pattern is shown.

[0253] Example 21: Preparation of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide Crystal Form S

[0254] 300 μL of 2-methyltetrahydrofuran was added to 20 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolin-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, stirred at room temperature for 20 h, filtered, and dried to obtain an off-white solid. This crystal form was named Crystal Form S.

[0255] The obtained sample was subjected to X-ray powder measurement using Cu-ka radiation, and it had substantially the same Fig.32 Example 22: Preparation of Amorphous N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide

[0256] 3.5 mL of dichloromethane was added to 100 mg of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, and the mixture was stirred and dissolved. The solvent was dried by vacuum rotary evaporator to obtain an off-white solid. XRD characterization showed that the solid was amorphous, and the amorphous had substantially the following properties: Fig.33 The X-ray powder diffraction pattern and Fig.34 Thermogravimetric analysis spectrum shown.

[0257] Test Example 1: Stability Test

[0258] In order to investigate the stability of various crystal forms prepared in the present invention, the crystal form A prepared in Example 1, the crystal form G prepared in Example 10, and the crystal form H prepared in Example 11 were placed under high temperature (60°C), high humidity (92.5% RH) and light (4500lx±500lx) conditions for 30 days, and samples were taken at 5 days, 10 days and 30 days, respectively, and XRD, HPLC and moisture were tested, and the results were compared with those of day 0 ( Figure 35-Figure 37 ), the result is as follows:

[0259] Table 9 Stability test data of factors affecting Form A

[0260]

[0261] Table 10 Stability test data of factors affecting Form G

[0262]

[0263] Table 11 Stability test data of factors affecting crystal form H

[0264]

[0265] From Table 9 and Fig.35 It can be seen that the crystal morphology and moisture content of Form A can remain stable under high temperature (60°C), high humidity (92.5% RH) and light conditions for 30 days, and the purity does not decrease significantly. The above experimental results show that Form A has good crystal stability and chemical stability. From Table 10 and Fig.36 It can be seen that the crystal form G can remain stable under high temperature (60°C), high humidity (92.5% RH) and light conditions for 30 days. The above experimental results show that the crystal form G has good crystal stability. From Table 11 and Fig.37 It can be seen that the crystal form H can maintain a stable crystal morphology under high temperature (60°C), high humidity (92.5% RH) and light conditions for 30 days. The above experimental results show that the crystal form H has good crystal stability.

[0266] Test Example 2: Hygroscopicity Study

[0267] In order to investigate the hygroscopicity of various crystal forms prepared in the present invention, the crystal form A prepared in Example 1, the crystal form B prepared in Example 5, the crystal form F prepared in Example 9, the crystal form G prepared in Example 10, the crystal form H prepared in Example 11 and the amorphous sample prepared in Example 22 were placed in a dynamic moisture adsorption instrument to investigate the weight change of the samples in the range of 0-98%-0 humidity. The hygroscopicity results of different crystal forms at 80% to 98% humidity are shown in Table 12, and the corresponding DVS curves are shown in Table 13. Figure 38-43 As shown:

[0268] Table 12 Hygroscopicity of different crystal forms at 80% RH ~ 98% RH

[0269]

[0270] From Table 12 and Figure 38-43 It can be seen that the hygroscopicity of Form A, Form B, Form F, Form G and Form H is relatively low, while the amorphous form has obvious hygroscopicity.

[0271] Test Example 3: Pharmacokinetics test in rats

[0272] 1. Purpose of the test

[0273] The concentration level of the raw material drug in plasma and its pharmacokinetic characteristics were investigated after a single oral administration of different crystalline forms of compound (I) to rats at the same dosage.

[0274] 2. Materials and Methods

[0275] 2.1. Drugs under investigation

[0276] Form A, off-white powdery solid, prepared in Example 1;

[0277] Form H, off-white powdery solid, prepared in Example 11;

[0278] 2.2 Experimental Animals

[0279] Twelve SD rats, 6 males and 6 females, weighing 220–240 g, were purchased from Hunan Slake Jingda Experimental Animal Co., Ltd. by Chengdu Enswell Biotechnology Co., Ltd., license number: SCXK (Xiang) 2019-0004.

[0280] 2.3 Test methods

[0281] Weigh 60 mg of the test drug, add 0.8 mL of DMSO, vortex mix, then add 7.2 mL of 20% HP-β-CD and vortex to form a clear and transparent solution. Orally administer to rats at a volume of 4 mL / kg, and collect 0.5 mL of blood from the jugular vein before administration and 0.5 h, 1, 2, 4, 6, 8, and 24 h after administration, place in a test tube containing an anticoagulant (EDTA-K2), centrifuge at 4500 r / min for 10 min, separate the plasma, and store in a -80°C refrigerator.

[0282] 2.4. LC / MS / MS biological sample analysis:

[0283] Take 50 μL of plasma and mix it with 5 μL of working solution or blank dilution, add 150 μL of acetonitrile precipitant containing internal standard, vortex for 2 minutes, centrifuge at 12000r / min for 10 minutes, take 2 μL of supernatant and mix it with 200 μL of pure water: acetonitrile (1:1), and inject 3 μL for analysis.

[0284] 2.5 Test results:

[0285] After a single oral administration of different crystalline forms of drugs to male and female rats, the main pharmacokinetic parameters are shown in Table 13 below:

[0286]

[0287]

[0288] The results of pharmacokinetic tests showed that Form A and Form H had good pharmacokinetics in rats.

[0289] It is obvious to those skilled in the art that various modifications and changes may be made to the compounds of the present application and their preparation methods without departing from the spirit or scope of the present application. Therefore, the scope of protection of the present application covers various modifications and changes made to the present application, as long as the modifications or changes are within the scope covered by the claims and their equivalent embodiments.

Claims

1. Form A of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, whose X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 4.20±0.2°, 7.19±0.2°, 8.32±0.2°, 8.77±0.2°, 10.13±0.2°, 15.20±0.2°, 15.69±0.2°, 18.48±0.2°, 20.95±0.2° and 25.92±0.2°.

2. The crystalline form A according to claim 1, characterized in that The X-ray powder diffraction pattern of the crystalline form A has characteristic peaks at 2θ angles of 4.20±0.2°, 4.66±0.2°, 5.07±0.2°, 7.19±0.2°, 8.32±0.2°, 8.77±0.2°, 10.13±0.2°, 11.75±0.2°, 13.03±0.2°, 14.68±0.2°, 15.20±0.2°, 15.69±0.2°, 18.48±0.2°, 19.63±0.2°, 20.22±0.2°, 20.95±0.2°, 22.82±0.2°, 23.99±0.2°, 25.92±0.2° and 26.63±0.2°.

3. The crystalline form A according to claim 2, characterized in that: The X-ray powder diffraction pattern of the crystalline form A is substantially as shown in FIG1 .

4. The crystalline form A according to any one of claims 1 to 3, characterized in that The thermogravimetric analysis spectrum of the crystal form A is basically shown in Figure 2.

5. The method for preparing the crystalline form A according to any one of claims 1 to 3, characterized in that: An organic solvent is added to N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide until it is dissolved, pure water is slowly added dropwise for crystallization, the mixture is fully stirred for 3-24 hours, filtered, and dried to obtain Form A.

6. The method for preparing Form A according to claim 5, characterized in that: The organic solvent is one or more of methanol, ethanol, isopropanol, trifluoroethanol, acetone, butanone, N-methylpyrrolidone, acetonitrile, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, and dimethyl sulfoxide.

7. The crystalline form D of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide has an X-ray powder diffraction pattern with characteristic peaks at 2θ angles of 5.48±0.2°, 8.39±0.2°, 10.43±0.2°, 14.14±0.2°, 16.10±0.2°, 19.98±0.2°, 21.25±0.2°, 21.73±0.2°, and 23.29±0.2°.

8. The crystalline form D according to claim 7, characterized in that The X-ray powder diffraction pattern of the crystalline form D has characteristic peaks at 2θ angles of 5.48±0.2°, 8.39±0.2°, 9.43±0.2°, 10.43±0.2°, 10.86±0.2°, 12.19±0.2°, 13.47±0.2°, 14.14±0.2°, 16.10±0.2°, 16.93±0.2°, 17.71±0.2°, 18.50±0.2°, 18.82±0.2°, 19.98±0.2°, 21.25±0.2°, 21.73±0.2°, 23.29±0.2°, 24.21±0.2°, 25.31±0.2° and 28.15±0.2°.

9. The crystalline form D according to claim 8, characterized in that The X-ray powder diffraction pattern of the crystal form D is basically shown in Figure 7.

10. The crystalline form D according to any one of claims 7 to 9, characterized in that: The thermogravimetric analysis spectrum of the crystal form D is basically shown in Figure 8.

11. The crystalline form G of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide has an X-ray powder diffraction pattern with characteristic peaks at 2θ angles of 10.03±0.2°, 11.36±0.2°, 12.88±0.2°, 14.93±0.2°, 15.73±0.2°, 17.08±0.2°, 19.17±0.2°, 20.64±0.2° and 22.10±0.2°.

12. The crystalline form G according to claim 11, characterized in that The X-ray powder diffraction pattern of the crystalline form G has characteristic peaks at 2θ angles of 6.87±0.2°, 10.03±0.2°, 11.36±0.2°, 12.88±0.2°, 13.70±0.2°, 14.93±0.2°, 15.73±0.2°, 16.62±0.2°, 17.08±0.2°, 18.40±0.2°, 19.17±0.2°, 20.64±0.2°, 20.96±0.2°, 21.33±0.2°, 22.10±0.2°, 23.52±0.2°, 24.10±0.2°, 25.72±0.2°, 26.07±0.2° and 27.63±0.2°.

13. The crystalline form G according to claim 12, characterized in that: The X-ray powder diffraction pattern of the crystalline form G is basically shown in Figure 13.

14. The crystalline form G according to any one of claims 11 to 13, characterized in that: The thermogravimetric analysis spectrum of the crystal form G is basically shown in Figure 14.

15. The crystalline form H of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide has an X-ray powder diffraction pattern with characteristic peaks at 2θ angles of 8.70±0.2°, 14.89±0.2°, 16.63±0.2°, 17.19±0.2°, 17.80±0.2°, 19.08±0.2°, 21.55±0.2° and 22.77±0.2°.

16. The crystalline form H according to claim 15, characterized in that: The X-ray powder diffraction pattern of the crystalline form H has characteristic peaks at 2θ angles of 8.70±0.2°, 9.35±0.2°, 10.58±0.2°, 11.42±0.2°, 12.48±0.2°, 14.89±0.2°, 16.63±0.2°, 17.19±0.2°, 17.80±0.2°, 18.56±0.2°, 19.08±0.2°, 19.69±0.2°, 19.97±0.2°, 21.02±0.2°, 21.55±0.2°, 22.77±0.2°, 24.44±0.2°, 25.33±0.2°, 26.89±0.2° and 29.82±0.2°.

17. The crystalline form H according to claim 16, characterized in that: The X-ray powder diffraction pattern of the crystalline form H is basically shown in Figure 15.

18. The crystalline form H according to any one of claims 15 to 17, characterized in that: The thermogravimetric analysis spectrum of the crystal form H is basically shown in Figure 16.

19. Use of the crystalline form A of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide according to any one of claims 1 to 3 in the preparation of a medicament for preventing and / or treating a disease associated with a BET protein.

20. Use of the crystalline form D of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide according to any one of claims 7 to 9 in the preparation of a medicament for preventing and / or treating a disease associated with a BET protein.

21. Use of the crystalline form G of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide according to any one of claims 11 to 13 in the preparation of a medicament for preventing and / or treating a disease associated with a BET protein.

22. Use of the crystalline form H of N-ethyl-4-(5-(2-hydroxypropyl-2-yl)-3-(indolyl-1-yl)thiophene-2-yl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide according to any one of claims 15 to 17 in the preparation of a medicament for preventing and / or treating diseases associated with BET proteins.

23. The use according to any one of claims 19 to 22, characterized in that: The BET protein-related disease is selected from tumor disease, inflammatory disease, autoimmune disease or viral infection.

24. The use according to claim 23, characterized in that The tumor disease is selected from acute myeloid leukemia, acute T-cell leukemia, B-cell acute lymphoid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic granulocytic leukemia, monocytic leukemia, myeloblastic leukemia, promyelocytic leukemia, angiosarcoma, astrocytoma, basal cell carcinoma, bile duct cancer, bladder cancer, brain cancer, breast cancer, bronchial cancer, prostate cancer, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, colorectal cancer or non-small cell lung cancer.